News

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results...

Administering carfilzomib once a week significantly improves progression-free survival (PFS) and toxicity compared with twice a week among patients...

CHICAGO (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a...

CHICAGO: Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before...

When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine...

CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Dr Rob Weinkove spoke at our patient seminar on CAR T-Cell Therapy: a New Frontier in...

Take a look at the International Myeloma Foundation's Newsletter, the Myeloma Minute  

A Kiwi dad who's dying of lung cancer has been bypassing the Pharmac system to get cheap pharmaceuticals directly from India - and says thousands of...

Lack of access to effective treatments is forcing blood cancer patients to take desperate measures 12 April 2018 Lack of funded access to...

The IMF is very pleased to have established a partnership with AbbVie to conduct the largest, most comprehensive chart-review study of myeloma...

Multiple Myeloma action month March 2018: Thanks to medical innovation, Multiple Myeloma patients are living longer than ever before. Multiple...